行情

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

实时行情|Nasdaq Last Sale

14.93
-0.21
-1.39%
盘后: 15.51 +0.58 +3.88% 18:13 09/17 EDT
开盘
15.31
昨收
15.14
最高
15.31
最低
14.80
成交量
50.06万
成交额
--
52周最高
16.38
52周最低
1.870
市值
4.24亿
市盈率(TTM)
-27.1999
分时
5日
1月
3月
1年
5年
对关键医疗用品的需求持续增长
/PRNewswire/ -- The emergence of the pandemic has helped accelerate the growth of demand for diagnostic supplies such as ventilators, N95 masks, and PPE kits, which in turn is fueling the medical supplies market growth. The hospital medical equipment and s...
PR Newswire - PRF · 3天前
PDS Biotechnology 将出席奥本海默秋季医疗保健生命科学与医疗技术峰会
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune T-cell activating technology, announced today that its management will present at the Oppenh...
GlobeNewswire · 6天前
PDS 生物技术公司:最近 52 周高点(PDSB)
(MENAFN - Investor Brand Network) Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) traded today at $16.31, eclipsing its 52-week high. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 471,00...
MENAFN · 09/09 19:26
Brief-PDS 在 PDS0101-KEYTRUDA 治疗头颈癌的第 2 期试验中完成安全队列的入组
reuters.com · 09/09 13:36
PDS Biotech 完成了 PDS0101-KEYTRUDA(R) 复发或转移性头颈癌 VERSATILE-002 2 期联合试验的导入安全队列的注册
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune T-cell activating technology, today announced that it has completed the enrollment of the le...
GlobeNewswire · 09/09 12:30
PDS Biotechnology 将出席 HC Wainwright 第 23 届年度全球投资大会
FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announ...
GlobeNewswire · 09/07 12:30
The Daily Biotech Pulse:默克发布双倍积极消息,安斯泰来自愿暂停基因治疗研究,Ascendis 产品
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
The Daily Biotech Pulse:VectivBio 在并购组合中,Sonnet Biotherapeutics 将候选人推向诊所,加拉帕戈斯群岛的首席执行官转型,Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/31 12:05
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解PDSB最新的财务预测,通过PDSB每股收益,每股净资产,每股现金流等数据分析PDS Biotechnology Corporation近期的经营情况,然后做出明智的投资选择。
分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测PDSB价格均价为19.71,最高价位25.00,最低价为15.00。
EPS
机构持股
总机构数: 62
机构持股: 1,105.47万
持股比例: 38.89%
总股本: 2,842.38万
类型机构数股数
增持
9
56.60万
建仓
26
318.13万
减持
4
23.40万
平仓
12
60.13万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.49%
制药与医学研究
-0.10%
高管信息
Non-Executive Chairman/Independent Director
Stephen Glover
President/Chief Executive Officer/Director
Frank Bedu-Addo
Chief Financial Officer/Chief Accounting Officer
Seth Van Voorhees
Chief Scientific Officer
Gregory Conn
Other
Lauren Wood
Director
Ilian Iliev
Independent Director
Kamil Ali-Jackson
Independent Director
Otis Brawley
Independent Director
Gregory Freitag
Independent Director
Richard Sykes
暂无数据
PDSB 简况
PDS Biotechnology Corp(原名:Edge Therapeutics, Inc.)是一家免疫肿瘤学公司。该公司致力于开发一系列临床阶段免疫疗法。其治疗方法用于治疗各种早期和晚期癌症,包括头颈癌、前列腺癌、乳腺癌、宫颈癌、肛门癌和其他癌症。Versamune是其合成的脂质免疫治疗平台。其主要候选产品PDS0101是一种现成的免疫治疗剂,通过皮下注射给药。其产品还包括PDS0102、PDS0103和PDS0104。其基于Versamune的产品系列均通过皮下注射进行。DS0102正在开发用于治疗前列腺癌和乳腺癌。PDS0103基于粘蛋白-1(MUC-1)致癌C末端区域的新型激动剂抗原。PDS0104正在开发用于治疗黑素瘤。

微牛提供PDS Biotechnology Corp(NASDAQ-PDSB)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PDSB股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PDSB股票基本功能。